Figure 3.
Cumulative incidence of relapse in patients with R/R FLT3+ AML in the gilteritinib arm. (A) Cumulative incidence of relapse after CR. (B) Cumulative incidence of relapse after CRc.

Cumulative incidence of relapse in patients with R/R FLT3+ AML in the gilteritinib arm. (A) Cumulative incidence of relapse after CR. (B) Cumulative incidence of relapse after CRc.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal